EGFR and paronychia: The research conducted by Soria et al in 2018,[19] titled “Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer,” boasts the strongest Citation Burst in recent 5 years (2018–2023, strength 11.01), their work analyzed the risk of paronychia while Osimertinib was applied in treatment of non-small-cell lung cancer.